Efficacy and safety of the S-1, nab-paclitaxel, and gemcitabine triplet regimen in patients with resected pancreatic ductal adenocarcinoma
{{output}}
Objective: To evaluate the safety, feasibility, and efficacy of an S-1-based triplet regimen (with nab-paclitaxel and gemcitabine) as adjuvant therapy following curative resection for pancreatic ductal adenocarcinoma (PDAC). ... ...
